MET and renal carcinoma: Combined inhibition of MET and EGFR showed improved PFS in patients with NSCLC with MET overexpression; however, the study was halted prematurely because of an increased rate of interstitial lung disease.344 Similar antitumor effects have been noted in renal cancer xenografts treated with therapies targeted at both VEGF and MET.345